# Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium

> **NCT00941057** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 43 (actual)

## Conditions studied

- Pharmacology, Clinical

## Interventions

- **DRUG:** BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium
- **DRUG:** BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)
- **DRUG:** BAY 86-7660,levomefolate calcium

## Key facts

- **NCT ID:** NCT00941057
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2009-12
- **Final completion:** 2010-01
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2016-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00941057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00941057, "Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00941057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*